Stockscreener 앱 받기
10.68
0.61%
0.07
전일 마감가:
$10.61
열려 있는:
$10.62
하루 거래량:
5.66M
Relative Volume:
0.48
시가총액:
$12.45B
수익:
$14.33B
순이익/손실:
$-3.79B
주가수익비율:
-3.3691
EPS:
-3.17
순현금흐름:
$1.84B
1주 성능:
+8.27%
1개월 성능:
+20.21%
6개월 성능:
-1.70%
1년 성능:
-8.45%
1일 변동 폭
$10.62
$10.81
1주일 범위
$9.87
$10.81
52주 변동 폭
$6.85
$13.55
비아트리스 Stock (VTRS) Company Profile
명칭
Viatris Inc
전화
(724) 514-1465
주소
1000 MYLAN BOULEVARD, CANONSBURG
VTRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
10.68 | 12.37B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
153.16 | 68.30B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.15 | 47.37B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.69 | 43.29B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.25 | 20.49B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
313.36 | 14.16B | 2.99B | 1.21B | 1.13B | 25.06 |
비아트리스 Stock (VTRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-06 | 개시 | Goldman | Neutral |
| 2024-07-19 | 재개 | Jefferies | Buy |
| 2023-10-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2023-04-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-02-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-10 | 업그레이드 | UBS | Sell → Neutral |
| 2022-11-08 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2022-06-14 | 개시 | UBS | Sell |
| 2022-05-10 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 개시 | Citigroup | Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 개시 | Argus | Hold |
| 2020-12-14 | 개시 | Bernstein | Mkt Perform |
모두보기
비아트리스 주식(VTRS)의 최신 뉴스
Stock Analysis | Viatris OutlookMixed Signals Emerge Amid Weak Technicals and Strong Fundamentals - AInvest
Jefferies Adjusts Price Target on Viatris to $14 From $13, Maintains Buy Rating - MarketScreener
What are the risks of holding Viatris Inc.Weekly Stock Summary & Stock Market Timing Techniques - classian.co.kr
Viatris Inc. Consolidation Zone May Signal Accumulation2025 Market WrapUp & High Conviction Investment Ideas - newsyoung.net
David Einhorn's Greenlight Capital Boosts Fluor Corp, Exits Viatris, Peloton, and Kyndryl - AInvest
Trump EO to bolster stockpile of active pharmaceutical ingredients for drugs - Seeking Alpha
Viatris Signals Ongoing Strategic Overhaul, Promises Update In Q3 - insights.citeline.com
Saudi Arabia Generic Drugs Market Outlook Report 2025-2033 | Government Cost-Cutting, Local Manufacturing, and Public Awareness Fuel Rapid Growth - GlobeNewswire Inc.
5 Must-Read Analyst Questions From Viatris’s Q2 Earnings Call - Yahoo Finance
Day 5 of Gains Streak for Viatris Stock with 19% Return (vs. -14% YTD) [8/13/2025] - Trefis
CEO Makes Bold Move with Major Viatris Stock Purchase - TipRanks
Viatris CEO Smith buys $219k in company stock By Investing.com - Investing.com Nigeria
Viatris CEO Smith buys $219k in company stock - Investing.com India
Viatris CEO Smith Buys 22K Shares at $9.99/Share on August 12, 2023. - AInvest
Avantor, Viatris, and Amneal Stocks Trade Up, What You Need To Know - TradingView
VTRS Q2 Deep Dive: Pipeline Progress and Cost Discipline Drive Results Amid Industry Headwinds - ca.finance.yahoo.com
Bruker, Viatris, Sotera Health Company, Align Technology, and Omnicell Stocks Trade Up, What You Need To Know - Yahoo Finance
Viatris first to win US approval for generic Venofer - The Pharma Letter
Brufen Maker Viatris Fails To Halt Rival's 'Brisen' TM Quest - Law360
Iron Sucrose Competition Expands With Viatris and Amphastar FDA Approvals - insights.citeline.com
Viatris wins FDA nod for generic iron sucrose injection targeting Daiichi’s Venofer - MSN
Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S. - BioSpace
Why Viatris (VTRS) Is Up 10.3% After Beating Q2 Estimates and Securing FDA Generic Win - simplywall.st
Ampicillin Market Driven by Rising Bacterial Infections - openPR.com
Sector Update: Health Care - MarketScreener
Merz Asks UPC To Bar Viatris Generic MS Drug - Law360
FDA Approvals for Iron Sucrose Products by Viatris, Amphastar Pharmaceuticals - AInvest
Why Viatris (VTRS) Stock Is Up Today - Yahoo Finance
Viatris Shares Climb Following FDA Clearance of First Generic Iron Sucrose Injection - MSN
Viatris stock rises after FDA approval of first generic iron sucrose By Investing.com - Investing.com South Africa
Viatris's Generic Iron Sucrose Injection Approval: A Strategic Win for Market Share and Cost-Saving in Healthcare - AInvest
Viatris stock rises after FDA approval of first generic iron sucrose - Investing.com Australia
FDA approves Viatris’ first generic iron sucrose injection for anemia By Investing.com - Investing.com Australia
FDA approves Viatris’ first generic iron sucrose injection for anemia - Investing.com
Viatris announces FDA approval for Iron Sucrose Injection - TipRanks
Viatris Inc. Reports Strong Q2 2025 Results - TipRanks
Carpmaels and A&O Shearman file first SPC suit at UPC for Merz against Viatris - JUVE Patent
Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates - MSN
Viatris (VTRS) Gets a Sell from Bank of America Securities - The Globe and Mail
EpiPen patent expiry opens new era for innovation - MSN
Viatris Earnings Call: Growth Amid Challenges - The Globe and Mail
Viatris aims for top-half 2025 revenue and EPS guidance while advancing late-stage pipeline - MSN
Research Alert: CFRA Keeps Sell Opinion On Shares Of Viatris Inc. - 富途牛牛
Goldman Sachs Adjusts Price Target on Viatris to $11 From $10, Maintains Neutral Rating - MarketScreener
Will Viatris’ (VTRS) Leadership Moves and Steady Outlook Signal Resilience or Ongoing Transition? - simplywall.st
Viatris Inc. (NASDAQ:VTRS) Q2 2025 Earnings Call Transcript - Insider Monkey
Viatris: Q2 Earnings Snapshot - Connecticut Post
Viatris To Seek FDA Approval For MR-141 In Presbyopia In 2H, 2025Did The Stock Catch Your Eye? - RTTNews
Viatris Reports Mixed Q2 Earnings Amid Pipeline Progress and Operational Challenges - AInvest
Viatris Inc (VTRS) Q2 2025 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges By GuruFocus - Investing.com Canada
Viatris 2025 Q2 Earnings Narrowed Losses Amid Revenue Decline - AInvest
비아트리스 (VTRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.18%
0.05%
자본화:
|
볼륨(24시간):